Earnings
Home›Earnings›Previews›Moderna stock surges after Phase 3 cancer trial win
Moderna stock surges after Phase 3 cancer trial win
The Phase 3 result against the standard of care drove the shares up 131%, and short sellers lost $4.8 billion, according to Decrypt.
Moderna shares jumped sharply after the company reported a Phase 3 win in a cancer study, with the outcome described as outperforming the current standard of care.
Decrypt reports the stock doubled, rising 131% on the news.
The same reporting said the rally left short sellers down $4.8 billion, reflecting the magnitude of the post-announcement move.
← Newer storyGold jumps toward $4,500 as Treasury buyback pulls US yields lowerOlder story →Burlington signs 44,070 sf lease at Bay Ridge’s Century Marketplace